Alpha 2.0
Login Register
» Authors » Alessio Lupi

Alessio Lupi

Explore the profile of Alessio Lupi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 14
Citations 137
Followers 0
Related Specialties
Oncology
General Medicine
Biochemistry
Top 10 Co-Authors
Rossana Berardi
Federica Pecci
Riccardo Giampieri
Luca Cantini
Edoardo Lenci
Enrica Giglio
Sonia Crocetti
Alessandro Bittoni
Cecilia Copparoni
Cristiano Felicetti
Published In
J Clin Med
Cancers (Basel)
Front Oncol
Nucleic Acids Res
Explor Target Antitumor Ther
Affiliations
Soon will be listed here.
Recent Articles
1.
Current Evidence and Future Perspectives about the Role of PARP Inhibitors in the Treatment of Thoracic Cancers
Parisi A, Rossi F, De Filippis C, Paoloni F, Felicetti C, Mammarella A, et al.
Onco Targets Ther . 2023 Jul; 16:585-613. PMID: 37485307
In recent years, poly (ADP-ribose) polymerase (PARP) inhibition has become a promising therapeutic option for several tumors, especially for those harboring a BRCA 1-2 mutation or a deficit in the...
2.
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study
Cantini L, Paoloni F, Pecci F, Spagnolo F, Genova C, Tanda E, et al.
J Natl Cancer Inst . 2023 Apr; 115(7):796-804. PMID: 37042716
Background: Real-life spectrum and survival implications of immune-related adverse events (irAEs) in patients treated with extended interval dosing (ED) immune checkpoint inhibitors (ICIs) are unknown. Methods: Characteristics of 812 consecutive...
3.
Hemoglobin and Neutrophil Count as Prognostic Factors in Cholangiocarcinoma Patients in 2nd Line Treatment Setting: Results from a Small Monocentric Retrospective Study
Liguori C, Copparoni C, Felicetti C, Pecci F, Lupi A, Pinterpe G, et al.
Curr Oncol . 2023 Jan; 30(1):1032-1045. PMID: 36661728
Background: Unresectable cholangiocarcinoma prognosis can be extremely variable due to different symptoms and sites of disease involvement at diagnosis and unpredictable chemotherapy response rates. Most patients will usually receive 1st...
4.
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment
Pretta A, Ziranu P, Giampieri R, Donisi C, Cimbro E, Spanu D, et al.
Dig Liver Dis . 2022 Dec; 55(5):655-660. PMID: 36513569
Background: Association between pancreatic ductal adenocarcinoma (PDAC) and type 2 diabetes mellitus (DM2) has long been evaluated. Indeed, DM2 can be both an epiphenomenon of PDAC and a risk factor....
5.
The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives
Cognigni V, Pecci F, Lupi A, Pinterpe G, De Filippis C, Felicetti C, et al.
Cancers (Basel) . 2022 Oct; 14(19). PMID: 36230686
During the last decade, the identification of oncogenic driver mutations and the introduction of tyrosine kinase inhibitors (TKIs) in daily clinical practice have substantially revamped the therapeutic approach of oncogene-addicted,...
6.
Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis
Lenci E, Marcantognini G, Cognigni V, Lupi A, Rinaldi S, Cantini L, et al.
Explor Target Antitumor Ther . 2022 Sep; 2(3):227-239. PMID: 36046436
Aim: The role of tumor burden (TB) for patients with non-small cell lung cancer (NSCLC) receiving immunotherapy is still unknown. The aim of this analysis was to analyze the prognostic...
7.
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients
Mariani S, Puzzoni M, Giampieri R, Ziranu P, Pusceddu V, Donisi C, et al.
Front Oncol . 2022 May; 12:852583. PMID: 35530345
Background: Rechallenge with EGFR inhibitors represents a promising strategy for patients with RAS wild type (WT) colorectal cancer (CRC) but definitive selection criteria are lacking. Recently, the RAS WT status...
8.
Retrospective Comparative Analysis of KRAS G12C . Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab
Giampieri R, Lupi A, Ziranu P, Bittoni A, Pretta A, Pecci F, et al.
Front Oncol . 2021 Oct; 11:736104. PMID: 34660299
Background: KRAS mutations in metastatic colorectal cancer (mCRC) define a subset of tumors that have primary resistance to anti-EGFR-based therapy. Data concerning whether different KRAS mutations may also have a...
9.
Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer
Pecci F, Cantini L, Bittoni A, Lenci E, Lupi A, Crocetti S, et al.
Curr Treat Options Oncol . 2021 Jun; 22(8):69. PMID: 34110510
Advanced colorectal cancer (CRC) is a heterogeneous disease, characterized by several subtypes with distinctive genetic and epigenetic patterns. During the last years, immune checkpoint inhibitors (ICIs) have revamped the standard...
10.
Seroprevalence of SARS-CoV-2-Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy
Cantini L, Bastianelli L, Lupi A, Pinterpe G, Pecci F, Belletti G, et al.
J Clin Med . 2021 Apr; 10(7). PMID: 33916569
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence in cancer patients may vary widely dependent on the geographic area and this has significant implications for oncological care. The aim of...